摘要
目的探讨福多司坦治疗慢性阻塞性肺疾病(COPD)的临床疗效及对激素敏感性的影响。方法将120例COPD急性加重期患者随机分为对照组和观察组,各60例。两组均给予常规治疗,对照组患者加用氨溴索,观察组患者加用福多司坦。结果观察组患者总有效率为93.33%,显著高于对照组的86.67%(P<0.05)。治疗后,两组患者肺功能指标均较前有显著升高(P<0.05),观察组第1秒用力呼气末容积(FEV1)占预计值百分比(FEV1%),肺活量(FVC)及FEV1/FVC%较对照组明显升高(P<0.05),而两组患者治疗后FVC间未见明显差异(P>0.05);治疗后,对照组患者人组蛋白脱乙酰化酶2(HDAC2)水平与治疗前无明显差异(P>0.05),而观察组患者显著上升(P<0.05);治疗过程中不良反应发生率两组间无明显差异(P>0.05)。结论加用福多司坦治疗COPD,能有效提高治疗有效率并改善肺功能,同时改善患者的激素抵抗作用。
Objective To investigate tbe clinical effect of fudosteine in tbe treatment of cbronic obstructive pulmonary disease(COPD) and its influence on tbe bormone sensitivity. Methods 120 cases of acute exacerbation COPD were randomly divided into tbe control group and tbe observation group,60 cases in eacb group. Tbe two groups were given tbe conventional treatment. Tbe control group was added witb ambroxol injection,wbile tbe observation group was added witb fudosteine. Results Tbe total effective rate in tbe observation group was 93. 33% ,wbicb was significantly bigber tban 86. 67% in tbe control group( P 〈 0. 05). Tbe lung function indexes after treatment in tbe two group were significantly improved compared witb before treatment( P 〈 0. 05);FEV1%,FVC and FEV1/FVC% in tbe observation group were significantly increased compared witb tbe control group( P 〈 0. 05),wbile FVC after treatment bad no statis-tical difference between tbe two groups( P 〉 0. 05);tbe HDAC2 level after treatment in tbe control group sbowed no statistically signif-icant difference compared witb before treatment( P〉 0. 05 ),wbile wbicb in tbe observation group was increased significantly ( P 〈 0. 05). Tbe occurrence rate of adverse reactions during treatment bad no significant difference between tbe two groups( P〉0. 05). Conclusion Adding fudosteine in tbe treatment of COPD can effectively increase tbe effective rate and improve tbe pulmonary func-tion,at tbe same time improves tbe bormone resistant role.
出处
《中国药业》
CAS
2015年第16期60-62,共3页
China Pharmaceuticals
关键词
福多司坦
慢性阻塞性肺疾病
激素抵抗
安全性
fudosteine
cbronic obstructive pulmonary disease
bormone resistance
safety